IP Library Granted Patent US 9,017,980
Granted Patent B2
US 9,017,980 · App. 13/972,167 · Granted Apr 28, 2015

Variant forms of urate oxidase and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,980
App. No.
13/972,167
Granted
Apr 28, 2015
Kind
B2
Abstract

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Claims (21)

1. A method for producing a uricase comprising the steps of:

(i) culturing a host cell comprising a vector comprising a nucleic acid sequence encoding a uricase

comprising a mammalian uricase amino acid sequence truncated at the amino terminus or the carboxy terminus or both the amino and carboxy termini by 1-6 amino acids and further comprising an amino acid substitution with threonine at position 7 (D7T), an amino acid substitution at position 46 (S46T), an amino acid substitution with lysine at position 291 (R291K) and an amino acid substitution with serine at position 301 (T301S), said truncation and amino acid substitution being relative to an amino acid sequence of SEQ ID NO:11;

wherein the nucleic acid sequence is operatively linked to a heterologous promoter under conditions such that the nucleic acid sequence is expressed by the host cell; and

(ii) isolating the expressed uricase.

2. The method of claim 1 , wherein the expressed uricase comprises an amino terminal amino acid selected from alanine, glycine, proline, serine, or threonine.

3. The method of claim 1 , wherein the expressed uricase comprises an amino terminal threonine.

4. The method of claim 1 , wherein the expressed uricase comprises an amino terminal methionine.

5. The method of claim 1 , wherein the uricase is conjugated with a polymer.

6. The method of claim 1 , wherein the heterologous promoter is an osmB promoter.

7. The method of claim 3 , wherein the expressed uricase consists of the amino acid sequence of SEQ ID NO: 8.

8. The method of claim 3 , wherein the expressed uricase comprises the amino acid sequence of SEQ ID NO: 8.

9. The method of claim 4 , wherein the expressed uricase consists of the amino acid sequence of SEQ ID NO: 7.

10. The method of claim 4 , wherein the expressed uricase comprises the amino acid sequence of SEQ ID NO: 7.

11. The method of claim 5 , wherein the polymer is selected from the group consisting of poly(ethylene glycol), dextran, polypropylene glycol, hydroxypropylmethyl cellulose, carboxymethylcellulose, polyvinyl pyrrolidone and polyvinyl alcohol.

12. The method of claim 5 , wherein the uricase is a polyethylene glycol—uricase conjugate.

13. The method of claim 12 , wherein the conjugate comprises 2 to 12 polyethylene glycol molecules on each uricase subunit.

14. The method of claim 12 , wherein each polyethylene glycol molecule has a molecular weight between about 1 kD and 100 kD.

15. The method of claim 13 , wherein each polyethylene glycol molecule has a molecular weight between 1 kD and 50 kD.

16. The method of claim 13 , wherein each polyethylene glycol molecule has a molecular weight between 5 kD and 20 kD.

17. The method of claim 13 , wherein each polyethylene glycol molecule has a molecular weight of 10 kD.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SELLER'S NAME AND EXECUTION DATE PREVIOUSLY RECORDED ON REEL 032675 FRAME 0936. ASSIGNOR(S) HEREBY CONFIRMS THE SELLER'S NAME SHOULD READ SAVIENT PHARMA HOLDINGS, INC. AND THE EXECUTION DATE FOR BOTH PARTIES SHOULD READ 01/09/2014. Recorded Jun 16, 2023
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 064009/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 062279/0512 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 061805 FRAME 0076. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 1, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062073/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC
Reel/Frame 061805/0076 →
CHANGE OF NAME Recorded Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →
CHANGE OF NAME Recorded Nov 18, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 040648/0367 →
PATENT SECURITY AGREEMENT Recorded Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0049 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2014
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, LLC
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 032675/0936 →
SECURITY AGREEMENT Recorded Mar 4, 2014
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 032384/0285 →
SECURITY AGREEMENT Recorded Feb 21, 2014
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 032319/0077 →